This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Dilaforette Ab. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Dagmar Pikas: Innovator in Sickle Cell Disease Treatment
Introduction
Dagmar Pikas is a notable inventor based in Uppsala, Sweden. She has made significant contributions to the field of medical research, particularly in the treatment of sickle cell disease. Her innovative approach has led to the development of a unique patent that addresses critical health challenges.
Latest Patents
Dagmar Pikas holds a patent for the "Use of chemically modified heparin derivatives in sickle cell disease." This invention relates to chemically modified heparin designed for the treatment of sickle cell disease. The modified heparin exhibits an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg, and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. This patent represents a significant advancement in therapeutic options for patients suffering from this condition.
Career Highlights
Throughout her career, Dagmar has worked with various companies, including Dilaforette AB and Modus Therapeutics AB. Her work in these organizations has allowed her to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Dagmar has collaborated with notable professionals such as Hans-Peter Ekre and Anna Leitgeb. These partnerships have enhanced her research and development efforts, leading to innovative solutions in the medical field.
Conclusion
Dagmar Pikas is a pioneering inventor whose work in the treatment of sickle cell disease has the potential to improve the lives of many patients. Her contributions to medical research and her innovative patent highlight her commitment to advancing healthcare solutions.